

ONCOLOGY CLINICAL NOTE

Patient Name: Linda Garcia
Date of Birth: December 3, 1955 (Age: 69)
Date of Note: November 18, 2025
Diagnosis: Malignant melanoma of skin, unspecified (ICD-10: C43.9)

HISTORY OF PRESENT ILLNESS

Ms. Garcia is a 69-year-old female with a diagnosis of cutaneous melanoma (C43.9). She has a history of prior treatment with immune checkpoint inhibition. She presents today for continuation of therapy and review of biomarker status.

LABORATORY & BIOMARKER RESULTS

Molecular and immunohistochemical testing was performed to guide ongoing management. The results are summarized below:

Biomarker / Test	Result	Clinical Interpretation
PD-L1 Expression	Positive (30%)	Moderate expression. Predictive of continued response to PD-1 blockade immunotherapy.
BRAF Mutation Status	Wild Type	Negative for BRAF V600E/K mutations. Targeted BRAF/MEK inhibitor therapy is not indicated; immunotherapy remains the primary systemic modality.

ASSESSMENT

The patient has metastatic or unresectable melanoma. Biomarker profiling confirms BRAF Wild Type status and PD-L1 positivity. Given her clinical status and biomarker profile, continuation of anti-PD-1 immunotherapy is appropriate.

TREATMENT PLAN

1. Pharmacotherapy

- **Continue Nivolumab:** Maintain current immunotherapy regimen.
- **Dosing:** Administer per standard flat-dosing or weight-based protocol (e.g., 240 mg q2w or 480 mg q4w).

2. Monitoring & Follow-up

- **Immune-Related Adverse Events (irAEs):** Monitor for signs of immune-mediated toxicity, including rash, diarrhea/colitis, pneumonitis, hepatitis, and thyroid dysfunction.
- **Clinical Evaluation:** Assessment of performance status and physical exam prior to each cycle.

3. Administrative & Coverage

- **Insurance Provider:** UnitedHealth
- **Policy Number:** INS44556
- **Status:** Active (Coverage verified Jan 2025 – Dec 2025)
- **Action:** Ensure re-authorization is on file for maintenance dosing period.

Electronically Signed By:
[Provider Name, MD/DO]
Department of Oncology